|
|
Article: Rigel Begins U.S. Clinical Testing of Allergy Drug.
- Article from:
- PR Newswire
- Article date:
- January 13, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Efficacy Data Expected to be Available Mid-Year
Rigel Pharmaceuticals, Inc. has initiated clinical testing in the United States for the company's first product, a drug to treat allergic rhinitis.
The experimental compound, R112, is the first of a new class of drug directed at immune blood cells called mast cells. Activation of these cells is one of the earliest steps in the initiation of an inflammatory response in allergy and asthma.
"Rigel's investigational drug represents a novel approach for intervening in the allergic process," said Harold S. Nelson, M.D., the study's lead investigator and professor of medicine at National Jewish Medical ...